by: Parent Project Muscular Dystrophy
Edgewise Therapeutics recently joined PPMD for a breaking news community webinar, during which Edgewise provided an update on the recently released topline results from its CANYON double-blind, randomized, placebo-controlled design to investigate the effect of sevasemten on individuals with Becker muscular dystrophy. Moderated by PPMD’s Pat Furlong, Edgewise’s VP, Patient Advocacy and External Innovation, Abby Bronson, MBA and Chief Medical Officer Joanne Donovan, MD, PhD, gave context and greater detail to the the topline results and answered questions from the community.
